An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.

There is a requirement for efficacious and safe medicines to treat diseases with high unmet need. The resurgence in αv-RGD integrin inhibitor drug discovery is poised to contribute to this requirement. However, drug discovery in the αv integrin space is notoriously difficult due to the receptors being structurally very similar as well as the polar zwitterionic nature of the pharmacophore. This Review aims to guide drug discovery research in this field through an αv inhibitor toolbox, consisting of small molecules and antibodies. Small-molecule αv tool compounds with extended profiles in αvβ1, 3, 5, 6 and 8 cell adhesion assays, with key physicochemical properties, have been collated to assist in the selection of the right tool for the right experiment. This should also facilitate an understanding of partial selectivity profiles of compounds generated in different assays across research institutions. Prospects for further αv integrin research and the critical importance of target validation are discussed, where increased knowledge of the selectivity for individual RGD αv integrins is key. Insights into the design of small-molecule RGD chemotypes for topical or oral administration are provided and clinical findings on advanced molecules are examined.

[1]  W. Kaelin,et al.  Common pitfalls in preclinical cancer target validation , 2017, Nature Reviews Cancer.

[2]  R. Chambers,et al.  An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.

[3]  Niki Prakoura,et al.  NFκB-Induced Periostin Activates Integrin-β3 Signaling to Promote Renal Injury in GN. , 2017, Journal of the American Society of Nephrology : JASN.

[4]  Lisa M. Miller,et al.  Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins. , 2017, Journal of medicinal chemistry.

[5]  Benjamin Geiger,et al.  A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins , 2017, Scientific Reports.

[6]  J. Schwarzbauer,et al.  Minireview: Fibronectin in retinal disease , 2017, Experimental biology and medicine.

[7]  M. Gore,et al.  Randomized phase II study of the safety and efficacy of a human anti-{alpha}v integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results , 2016 .

[8]  Zhiwei Yang,et al.  Zwitterionic structures: from physicochemical properties toward computer-aided drug designs. , 2016, Future medicinal chemistry.

[9]  R. Harrison,et al.  Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.

[10]  R. Slack,et al.  Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand. , 2016, Biochemical pharmacology.

[11]  W. DeGrado,et al.  Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. , 2016, ACS medicinal chemistry letters.

[12]  Niroshini Nirmalan,et al.  “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives , 2016, Proteomes.

[13]  S. Lynn,et al.  Synthesis and determination of absolute configuration of a non-peptidic αvβ6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis. , 2016, Organic & biomolecular chemistry.

[14]  N. Henderson,et al.  αv integrins: key regulators of tissue fibrosis , 2016, Cell and Tissue Research.

[15]  Rachel C Chambers,et al.  Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.

[16]  B. Neuschwander‐Tetri,et al.  Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice , 2016, Cellular and molecular gastroenterology and hepatology.

[17]  K. Miller,et al.  Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.

[18]  Joachim P. Spatz,et al.  In vitro cancer cell-ECM interactions inform in vivo cancer treatment. , 2016, Advanced drug delivery reviews.

[19]  H. Kessler,et al.  Kleine Ursache, große Wirkung: Modifikation der Guanidiniumgruppe im RGD‐Motiv reguliert die Integrinsubtypselektivität , 2016 .

[20]  E. Novellino,et al.  Stabile Peptide statt “gestapelte Peptide”: hochaffine αvβ6‐selektive Integrinliganden , 2016 .

[21]  E. Novellino,et al.  Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands. , 2016, Angewandte Chemie.

[22]  H. Kessler,et al.  Small Cause, Great Impact: Modification of the Guanidine Group in the RGD Motif Controls Integrin Subtype Selectivity. , 2016, Angewandte Chemie.

[23]  J. Schellens,et al.  A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies , 2016, Investigational New Drugs.

[24]  D. Flint,et al.  Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2 , 2016, Pharmacology.

[25]  Zu-hua Gao,et al.  Arginine-Glycine-Aspartate–Binding Integrins as Therapeutic and Diagnostic Targets , 2016, American journal of therapeutics.

[26]  Beiyan Zou,et al.  Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay , 2016, Acta Pharmacologica Sinica.

[27]  J. Gauldie,et al.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox , 2015, Nature Reviews Drug Discovery.

[28]  H. R. Cheruku,et al.  Integrin αvβ6 sets the stage for colorectal cancer metastasis , 2015, Cancer and Metastasis Reviews.

[29]  C. Prakash,et al.  Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist , 2015, Drug Metabolism and Disposition.

[30]  John P. Overington,et al.  The promise and peril of chemical probes. , 2015, Nature chemical biology.

[31]  Katie Kingwell Fibrotic diseases: New tools to target an elusive integrin , 2015, Nature Reviews Drug Discovery.

[32]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[33]  Paul D Leeson,et al.  Molecular Property Design: Does Everyone Get It? , 2015, ACS medicinal chemistry letters.

[34]  W. DeGrado,et al.  The αvβ1 integrin plays a critical in vivo role in tissue fibrosis , 2015, Science Translational Medicine.

[35]  L. McIntosh,et al.  Arginine: Its pKa value revisited , 2015, Protein science : a publication of the Protein Society.

[36]  L. Duong,et al.  Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis , 2015, Oncology reports.

[37]  C. Bokemeyer,et al.  Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  T. Springer,et al.  Structural determinants of integrin β-subunit specificity for latent TGF-β , 2014, Nature Structural &Molecular Biology.

[39]  B. Coller,et al.  RUC-4: A Novel &agr;IIb&bgr;3 Antagonist for Prehospital Therapy of Myocardial Infarction , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[40]  M. Fray,et al.  Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents. , 2014, ACS medicinal chemistry letters.

[41]  J. Berlin,et al.  A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[42]  K. Aldape,et al.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[43]  Rhian Gabe,et al.  Therapeutic Targeting of Integrin αvβ6 in Breast Cancer , 2014, Journal of the National Cancer Institute.

[44]  O. Brand,et al.  Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease , 2014, Science Translational Medicine.

[45]  B. Hinz,et al.  Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. , 2014, Cardiovascular research.

[46]  H. Ueno,et al.  Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma , 2014, Investigational New Drugs.

[47]  L. Donnelly,et al.  Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses. , 2014, Advanced drug delivery reviews.

[48]  J. Verweij,et al.  Determining the optimal dose in the development of anticancer agents , 2014, Nature Reviews Clinical Oncology.

[49]  José Luis Alonso,et al.  Structural basis for pure antagonism of integrin αVβ3 by a high affinity form of fibronectin , 2014, Nature Structural &Molecular Biology.

[50]  L. Patterson,et al.  Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. , 2014, Journal of medicinal chemistry.

[51]  A. Perkins,et al.  Preclinical SPECT/CT Imaging of αvβ6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis , 2013, The Journal of Nuclear Medicine.

[52]  A. Kestranek,et al.  Chemiluminescent Nitrogen Detection (CLND) to Measure Kinetic Aqueous Solubility , 2013, Current protocols in chemical biology.

[53]  H. Kessler,et al.  Integrin modulators: a patent review , 2013, Expert opinion on therapeutic patents.

[54]  S. Barry,et al.  A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo , 2013, Oncogene.

[55]  Liang-Shang Gan,et al.  Plasma protein binding: from discovery to development. , 2013, Journal of pharmaceutical sciences.

[56]  H. Kessler,et al.  Tumor Targeting via Integrin Ligands , 2013, Front. Oncol..

[57]  D. Griggs,et al.  Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs , 2013, Nature Medicine.

[58]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[59]  R. Guha,et al.  Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.

[60]  N. Bogdanova,et al.  A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  D. Morel,et al.  In vitro investigation of integrin-receptor antagonist-induced vascular toxicity in the mouse. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[62]  D. Sheppard,et al.  Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. , 2012, American journal of respiratory and critical care medicine.

[63]  G. Minniti,et al.  Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. , 2012, Anticancer research.

[64]  S. Goodman,et al.  Integrins as therapeutic targets. , 2012, Trends in pharmacological sciences.

[65]  A. Pavlick,et al.  Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma , 2012, Investigational New Drugs.

[66]  Ken Grime,et al.  Optimisation of DMPK by the inhaled route: challenges and approaches. , 2012, Current drug metabolism.

[67]  Y. Vugmeyster,et al.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.

[68]  B. Coller,et al.  Structure-Guided Design of a High-Affinity Platelet Integrin αIIbβ3 Receptor Antagonist That Disrupts Mg2+ Binding to the MIDAS , 2012, Science Translational Medicine.

[69]  D. Cella,et al.  Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study , 2012, Melanoma research.

[70]  E. Novellino,et al.  Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site. , 2012, Journal of medicinal chemistry.

[71]  S. Robinson,et al.  The role of β3-integrins in tumor angiogenesis: context is everything. , 2011, Current opinion in cell biology.

[72]  M. Marahiel,et al.  Introducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonist. , 2011, Angewandte Chemie.

[73]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[74]  D. Cheresh,et al.  αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.

[75]  Darren V S Green,et al.  Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.

[76]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[77]  P. Fracasso,et al.  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer , 2011, Investigational New Drugs.

[78]  D. Schadendorf,et al.  A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma , 2011, British Journal of Cancer.

[79]  S. Bender,et al.  Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. , 2010, Cancer research.

[80]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[81]  Horst Kessler,et al.  Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.

[82]  Marian Brennan,et al.  Integrins as therapeutic targets: lessons and opportunities , 2010, Nature Reviews Drug Discovery.

[83]  M. Dolenc,et al.  Small molecule antagonists of integrin receptors. , 2010, Current medicinal chemistry.

[84]  Chris J Scotton,et al.  Bleomycin revisited: towards a more representative model of IPF? , 2010, American journal of physiology. Lung cellular and molecular physiology.

[85]  Ian Collins,et al.  Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.

[86]  C. Curti,et al.  Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides , 2010 .

[87]  J. Sosman,et al.  A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma , 2010, Cancer.

[88]  M. Campone,et al.  Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases , 2010, Asia-Pacific journal of clinical oncology.

[89]  A. Sonnenberg,et al.  Integrin–TGF‐β crosstalk in fibrosis, cancer and wound healing , 2010 .

[90]  A. Adamis,et al.  Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. , 2009, Archives of ophthalmology.

[91]  M. Serra,et al.  Small molecule integrin antagonists in cancer therapy. , 2009, Mini reviews in medicinal chemistry.

[92]  R. Stupp,et al.  Will integrin inhibitors have proangiogenic effects in the clinic? , 2009, Nature Medicine.

[93]  E. Novellino,et al.  Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity. , 2009, Angewandte Chemie.

[94]  H. Kessler,et al.  Bruch mit dem Dogma metallkoordinierender Carbonsäuren in Integrinliganden: Änderung von Selektivität und Aktivität durch Hydroxamsäuren als MIDAS‐Binder , 2009 .

[95]  D. Stupack,et al.  Agonizing integrin antagonists? , 2009, Cancer cell.

[96]  J. Norman,et al.  Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.

[97]  Simon J. F. Macdonald,et al.  Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet? , 2009, J. Chem. Inf. Model..

[98]  R. Fässler,et al.  Genetic and cell biological analysis of integrin outside-in signaling. , 2009, Genes & development.

[99]  A. Tolcher,et al.  Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.

[100]  R. Mirimanoff,et al.  CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. , 2008, Cancer research.

[101]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[102]  D. Shaw,et al.  Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth , 2008, Clinical Cancer Research.

[103]  S. Mousa,et al.  Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[104]  C. Schubert,et al.  Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies. , 2008, The Journal of organic chemistry.

[105]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[106]  William F. DeGrado,et al.  Small Molecule Inhibitors of Integrin α2β1 , 2007 .

[107]  S. Rodan,et al.  Involvement of αvβ3 integrins in osteoclast function , 2007, Journal of Bone and Mineral Metabolism.

[108]  J. Sutcliffe,et al.  Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. , 2007, Cancer research.

[109]  U. Reimer,et al.  Design and Synthesis of a New Class of Selective Integrin α5β1 Antagonists , 2007 .

[110]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[111]  M. Waring,et al.  A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[112]  D. Sheppard,et al.  Integrin αvβ5 Regulates Lung Vascular Permeability and Pulmonary Endothelial Barrier Function , 2007 .

[113]  L. P. Mašič Arginine mimetic structures in biologically active antagonists and inhibitors. , 2006, Current medicinal chemistry.

[114]  Dahua Zhang,et al.  Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study , 2006, Investigational New Drugs.

[115]  D. Shaw,et al.  A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo , 2006, Molecular Cancer Therapeutics.

[116]  B. González,et al.  Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector , 2006, International journal of cancer.

[117]  H. Kessler,et al.  Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.

[118]  Juan J. Marugan,et al.  Original articleNovel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin , 2006 .

[119]  T. Penning,et al.  Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists , 2006 .

[120]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[121]  Shobha N. Bhattachar,et al.  Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery. , 2006, Journal of pharmaceutical and biomedical analysis.

[122]  M. Ishikawa,et al.  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 2: Synthesis of potent αvβ3/αIIbβ3 dual antagonists , 2006 .

[123]  R. Willette,et al.  SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. , 2006, Investigative ophthalmology & visual science.

[124]  Hongwei Wu,et al.  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties , 2006 .

[125]  M. Jinnin,et al.  Increased Expression of Integrin αvβ5 Induces the Myofibroblastic Differentiation of Dermal Fibroblasts , 2006 .

[126]  J. Bennett,et al.  Structure and function of the platelet integrin αIIbβ3 , 2005 .

[127]  Jens Eickhoff,et al.  Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.

[128]  M. Dolenc,et al.  Dual antagonists of integrins. , 2005, Current medicinal chemistry.

[129]  G. Gordon,et al.  Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events , 2005, Journal of cellular and molecular medicine.

[130]  C. Leu,et al.  Nonpeptide αvβ3 antagonists : identification of potent, chain-shortened 7-oxo RGD mimetics , 2005 .

[131]  B. Tomczuk,et al.  Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core , 2005 .

[132]  G. Leo,et al.  1,2,3,4-Tetrahydroquinoline-containing αvβ3 integrin antagonists with enhanced oral bioavailability , 2004 .

[133]  Dana L. Johnson,et al.  Piperidine-containing β-arylpropionic acids as potent antagonists of αvβ3/αvβ5 integrins , 2004 .

[134]  R. Hynes The emergence of integrins: a personal and historical perspective. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[135]  D. Huryn,et al.  The identification and optimization of orally efficacious, small molecule VLA-4 antagonists. , 2004, Current topics in medicinal chemistry.

[136]  C. Leu,et al.  Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone , 2004 .

[137]  J. Marugan,et al.  Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands. , 2004, Bioorganic & medicinal chemistry letters.

[138]  P. Coleman,et al.  Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis , 2004 .

[139]  E. Novellino,et al.  Human Integrin αvβ5: Homology Modeling and Ligand Binding , 2004 .

[140]  M. Trikha,et al.  CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.

[141]  S. Andronati,et al.  Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. , 2004, Current medicinal chemistry.

[142]  K. Simon,et al.  Function-blocking Integrin αvβ6 Monoclonal Antibodies , 2004, Journal of Biological Chemistry.

[143]  P. Coleman,et al.  Non-peptide αvβ3 antagonists. Part 7: 3-Substituted tetrahydro-[1,8]naphthyridine derivatives , 2004 .

[144]  L. Tan,et al.  An efficient synthesis of an alphavbeta3 antagonist. , 2004, The Journal of organic chemistry.

[145]  B. Ma,et al.  Renal elimination of a novel and potent αvβ3 integrin antagonist in animals , 2004 .

[146]  C. Leu,et al.  Non-peptide αvβ3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint , 2003 .

[147]  M. Abraham,et al.  Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. , 2003, Journal of pharmaceutical sciences.

[148]  D. Sheppard,et al.  Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice , 2003 .

[149]  P. Coleman,et al.  Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. , 2003, Journal of medicinal chemistry.

[150]  Horst Kessler,et al.  Docking studies on αvβ3 integrin ligands: Pharmacophore refinement and implications for drug design , 2003 .

[151]  Timothy A. Springer,et al.  Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.

[152]  C. Leu,et al.  Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold , 2003 .

[153]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[154]  L. Ellis,et al.  Inhibition of integrin α5β1 function with a small peptide (ATN‐161) plus continuous 5‐FU infusion reduces colorectal liver metastases and improves survival in mice , 2003, International journal of cancer.

[155]  K. Ward,et al.  Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists , 2003 .

[156]  A. Kling,et al.  Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin α V β 3 antagonists , 2003 .

[157]  Andrea Vaupel,et al.  Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas. , 2003, Bioorganic & medicinal chemistry letters.

[158]  R. Volante,et al.  Highly regioselective Friedländer annulations with unmodified ketones employing novel amine catalysts: syntheses of 2-substituted quinolines, 1,8-naphthyridines, and related heterocycles. , 2003, The Journal of organic chemistry.

[159]  S. Barry,et al.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.

[160]  L. Schnapp,et al.  Integrin α8β1 mediates adhesion to LAP-TGFβ1 , 2002, Journal of Cell Science.

[161]  R. Wilder,et al.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.

[162]  Junichi Takagi,et al.  Global Conformational Rearrangements in Integrin Extracellular Domains in Outside-In and Inside-Out Signaling , 2002, Cell.

[163]  P. Coleman,et al.  Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics , 2002 .

[164]  Kathleen R. Lamborn,et al.  Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .

[165]  P. Coleman,et al.  Ligands to the integrin receptor αvβ3 , 2002 .

[166]  E. Lazarides,et al.  Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist. , 2002, Bioorganic & medicinal chemistry.

[167]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[168]  Klaus Schulten,et al.  A structural model for force regulated integrin binding to fibronectin's RGD-synergy site. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[169]  E. Topol,et al.  Glycoprotein IIb/IIIa antagonists - from bench to practice , 2002, Cellular and Molecular Life Sciences CMLS.

[170]  Horst Kessler,et al.  Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins , 2002 .

[171]  P. Coleman,et al.  Non-peptide αvβ3 antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl β-amino acids as aspartic acid replacements , 2002 .

[172]  M. Okada,et al.  Novel Malonamide Derivatives as αvβ3 Antagonists. Syntheses and Evaluation of 3-(3-Indolin-1-yl-3-oxopropanoyl)aminopropanoic Acids on Vitronectin Interaction with αvβ3 , 2001 .

[173]  Horst Kessler,et al.  Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library: New Selective αvβ3 Integrin Antagonists , 2001 .

[174]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[175]  K. Ward,et al.  Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[176]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[177]  F. Mitjans,et al.  In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .

[178]  R. Willette,et al.  Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .

[179]  R. Scarborough,et al.  Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. , 2000, Journal of medicinal chemistry.

[180]  W. F. Hoffman,et al.  Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist , 2000 .

[181]  Li Zhang,et al.  Ligand Binding to Integrins* , 2000, The Journal of Biological Chemistry.

[182]  F. Mitjans,et al.  Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. , 2000, European journal of cell biology.

[183]  D. Rockey,et al.  Expression of the Integrin α8β1 during Pulmonary and Hepatic Fibrosis , 2000 .

[184]  G. Hartman,et al.  αvβ3 Integrin antagonists as inhibitors of bone resorption , 2000 .

[185]  S. Barry,et al.  A Regulated Interaction between α5β1 Integrin and Osteopontin , 2000 .

[186]  P. Jadhav,et al.  Isoxazolines as Potent Antagonists of the Integrin αvβ3 , 2000 .

[187]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[188]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[189]  R. Jordan,et al.  Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins , 1998 .

[190]  William F. Westlin,et al.  A Peptidomimetic Antagonist of the Integrin αvβ3 Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy , 1998 .

[191]  T. Harada,et al.  Development of the new potent non-peptide gpIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique , 1997 .

[192]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[193]  J. Engel,et al.  Demonstration of non‐linear detection in ELISA resulting in up to 1000‐fold too high affinities of fibronogen binding to integrin αIIbβ3 , 1995 .

[194]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[195]  R. Gould,et al.  Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. , 1994, Journal of medicinal chemistry.

[196]  E. Wayner,et al.  Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface , 1991, The Journal of cell biology.

[197]  W. Carter,et al.  Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits , 1987, The Journal of cell biology.

[198]  Richard O. Hynes,et al.  Integrins: A family of cell surface receptors , 1987, Cell.

[199]  R. Hynes,et al.  Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin , 1986, Cell.

[200]  K. Ley,et al.  Integrin-based therapeutics : biological basis , clinical use and new drugs , 2016 .

[201]  H. Juhl,et al.  Precision Cut Cancer Tissue Slices in Anti-Cancer Drug Testing - , 2015 .

[202]  C. Belani,et al.  Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[203]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[204]  A. Tolcher,et al.  Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.

[205]  Nicola J. Rinaldi,et al.  Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation , 2008 .

[206]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[207]  R. Dubridge,et al.  Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. , 2006, Journal of experimental therapeutics & oncology.

[208]  J. Yergey,et al.  IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN v 3 ANTAGONIST IN RATS , DOGS , AND MONKEYS , 2004 .

[209]  H. Berman,et al.  Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .

[210]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .